EU-approved treatment for prostate cancer
The European Commission’s favorable opinion was based on a phase III study, conducted in 831 patients, which showed a 38% reduction in the risk of death compared to existing treatments. The European Commission has given the green light for a new treatment from Novartis for an advanced form of prostate cancer, the Swiss pharmaceutical giant … Read more